Record overview
Status and phase
Status: TERMINATED
Phase: PHASE2
Sponsor: Neovii Biotech
Condition: Breast Neoplasms, Breast Cancer
NCT00351858
Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
company focus on other projects